Device Trial Radar · NCT03761563
Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease
Last checked: Nov 20, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Feb 13, 2019
Primary completion
Jun 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Xtant MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 3, 2018
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.
Conditions
- Degenerative Disc Disease
Interventions
Fortilink IBF System with TETRAfuse TechnologyDevice
Cervical and lumbar fusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of cervical fusion evaluated by radiographic evidenceTime frame: 12 months
1 more outcomes with a free account
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Los Angeles Orthopedic Institute
Sherman Oaks, California
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.